During the past decade, MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Trium Analysis Online GmbH" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are "Breast Cancer" (2 trials), "Colorectal Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Estrogen Receptor Positive Breast Cancer" (1 trials) and "Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" in a lesser frequency.

Most popular intervention types in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Pertuzumab" (2 trials), "Trastuzumab" (2 trials), "5-FU/LV" (1 trials) and "5-Fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".